Literature DB >> 28081908

The impact on women's health and the cervical cancer screening budget of primary HPV screening with dual-stain cytology triage in Belgium.

Wiebren A A Tjalma1, Emily Kim2, Katleen Vandeweyer3.   

Abstract

Dual stain cytology, or "diagnostic cytology", offers a significant increase in sensitivity compared to cytology, with a slight decrease in specificity. This can reduce additional investigations like colposcopies, biopsies, and follow-up visits. Cervical cancer screening for women between 25 and 65 years of age with diagnostic cytology is estimated to reduce the incidence of cervical cancer by 36% and reduce annual cervical cancer mortalities by 40%. The reduced number of screening visits and the decrease in incidence and mortality will improve quality of life. In this article, a model was created to evaluate the cost-effectiveness of diagnostic cytology for Belgium. In this approach, precancerous cells are more likely to be immediately identified during the first screening visit. This reduces both the number and frequency of follow-up visits required. After two cycles (6 years), the prevalence of CIN and cervical cancer is decreased significantly in the screened population. At a population level, these shifts can reduce the screening budget by 21%, resulting in savings of 5.3 million euro a year in Belgium. Diagnostic cytology benefits all stakeholders involved in cervical cancer screening.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ASCUS; Budget; CINtec(®)PLUS Cytology test; Cost effective test; Diagnostic cytology; Dual stain cytology; Ki-67; LSIL; Screening; Triage; p16; p16/Ki-67 dual stain cytology

Mesh:

Year:  2017        PMID: 28081908     DOI: 10.1016/j.ejogrb.2017.01.010

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  7 in total

1.  Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study.

Authors:  Laura Gilbert; Sam Ratnam; Dan Jang; Reza Alaghehbandan; Miranda Schell; Rob Needle; Anne Ecobichon-Morris; Arnav Wadhawan; Dustin Costescu; Laurie Elit; Peter Wang; George Zahariadis; Max Chernesky
Journal:  Cancer Biomark       Date:  2022       Impact factor: 3.828

2.  miR-484 suppresses proliferation and epithelial-mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells.

Authors:  Yang Hu; Hong Xie; Yankun Liu; Weiying Liu; Min Liu; Hua Tang
Journal:  Cancer Cell Int       Date:  2017-03-07       Impact factor: 5.722

3.  Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology.

Authors:  Wichai Termrungruanglert; Nipon Khemapech; Tanitra Tantitamit; Piyalamporn Havanond
Journal:  J Gynecol Oncol       Date:  2018-11-08       Impact factor: 4.401

4.  Moving towards an organized cervical cancer screening: costs and impact.

Authors:  Mireia Diaz; David Moriña; Vanesa Rodríguez-Salés; Raquel Ibáñez; Josep Alfons Espinás; Silvia de Sanjosé
Journal:  Eur J Public Health       Date:  2018-12-01       Impact factor: 3.367

5.  Budget impact analysis of primary screening with the HPV test and genotyping against conventional cytology in Colombia

Authors:  Miguel Amézquita; Geny Carolina Silva; Diego Antonio Restrepo; Linda Margarita Ibata; Rafael Niño; Maximiliano Bustacara; Víctor Alexander Sáenz; Dieric Anderson Díaz; Milena Alarcón; Luz Adriana Quintero
Journal:  Biomedica       Date:  2022-06-01       Impact factor: 1.173

Review 6.  Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis.

Authors:  Nicolas Iragorri; Eldon Spackman
Journal:  Public Health Rev       Date:  2018-07-13

7.  Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007-2014.

Authors:  Xiaomeng Yue; Jane M Pruemer; Ana L Hincapie; Ziyad S Almalki; Jeff J Guo
Journal:  J Gynecol Oncol       Date:  2020-03-06       Impact factor: 4.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.